Participating in a clinical trial can offer several benefits:
• Closer Monitoring: Participants often receive more frequent and detailed medical attention.
• Contribution to Medicine: Participants in clinical trials help advance medical research and potentially benefit others in the future.
• Access to New Treatments: You might gain access to new therapies before they are widely available.
• Cost Reduction: Many clinical trials cover the cost of the treatment being studied.
It is important to consult with your healthcare provider to determine if a clinical trial is right for you and to discuss potential benefits and risks.
Current Trials:
By reducing inflammation, ziltivekimab may help to:
- Decrease the risk of cardiovascular events.
- Improve heart function.
- Enhance overall quality of life for patients with HF.
Contact: Charmaine Waters, Clinical Trial Coordinator,
charzipoo@gmail.com 604 831-1206
Ziltivekimab shows promising phase 2 results that have the potential for maximised efficacy and safety compared with other anti-inflammatory therapies.
Are you 18 years or older and have
- A diagnosis of heart failure (HF)?
- An Echocardiogram in the last 12 months?
Hermes EX6018-4915 is a phase III trial of ziltivekimab, a drug to target inflammation, for patients with heart failure and reduced or preserved ejection fraction.
HERMES
EX6018-4915
A previous trial, AZALEA-TIMI 71, terminated early due to greater than expected benefit with abelacimab and another trial showed abelacimab superior to enoxaparin in preventing venous thromboembolism.
Are you 65 to 74 years old with
- A diagnosis of Atrial Fibrillation (AF) or flutter?
- Do you have a condition associated with increased risk of bleeding?
- Are you planning the use of Aspirin or other antiplatelet agent?
Contact: Charmaine Waters, Clinical Trial Coordinator,
charzipoo@gmail.com 604 831-1206
LILAC-TIMI76 (ANT-010): is a phase lll trial of abeLacimab in the prevention of stroke and systemic embolism in high-risk patients with atrial fibrillation who have been deemed unsuitable for oral anticoagulation therapy.
LILAC-TIMI 76
(ANT-101)
Contact: Charmaine Waters, Clinical Trial Coordinator,
charzipoo@gmail.com 604 831-1206
Are you 45 years or older, and
- Managing your LDL-C with medical and dietary treatment?
- have experienced an acute coronary event in the last 3 months?
- Can be tested for the AA genotype at variant rs1967309 in the ADCY9 gene?
A previous study showed that patients with the AA genotype experienced fewer cardiovascular events with dalcetrapib.
DAL-302
